The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis (Q45016242)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis |
scientific article |
Statements
1 reference
The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis (English)
1 reference
1 reference
1 reference
E Eleftherakis-Papaiakovou
1 reference
E Terpos
1 reference
M Roussou
1 reference
D Heath
1 reference
D Christoulas
1 reference
N Anagnostopoulos
1 reference
K Tsionos
1 reference
P Croucher
1 reference
4 September 2008
1 reference
1 reference
1 reference
Identifiers
1 reference